Bevacizumab
- PDF / 169,280 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 121 Downloads / 178 Views
1 S
Brain oedema: case report A 48-year-old woman developed brain oedema during treatment with bevacizumab for radiation necrosis. The woman, who had breast cancer, was diagnosed with intracranial myxoid mesenchymal tumour with EWSR1-ATF1 gene fusion, for which she underwent total resection and subsequently exhibited recurrence of the myxoid mesenchymal tumour. After the recurrence, a ventriculo-peritoneal shunt was placed for management of obstructive hydrocephalus. She also received radiation therapy to the recurrent tumour sites. But, she developed radiation necrosis. She was then started receiving bevacizumab [dosage and route not stated] for the radiation necrosis. A positive radiographic response was eventually achieved. However, she also developed bevacizumab-associated brain oedema [duration of treatment to reaction onset not stated]. At a follow-up after 1 year, no evidence of tumour recurrence was noted [outcome of the reaction not stated]. Ward B, et al. Adult Intracranial Myxoid Mesenchymal Tumor with EWSR1-ATF1 Gene Fusion. World Neurosurgery 143: 91-96, Nov 2020. Available from: URL: http:// 803501147 doi.org/10.1016/j.wneu.2020.07.057
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
